Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  1998-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.ATV.18.10.1634PMID 9763537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The New England Journal

  2000cited by this paper
• Reduced transplant arteriosclerosis in plasminogen-deficient mice.

  1998cited by this paper
• 76 Reduced transplant arteriosclerosis in plasminogen deficient mice

  1997cited by this paper
• Plasma protein C inhibitor is elevated in survivors of myocardial infarction.

  1997cited by this paper
• Platelets and coronary artery disease.

  1996cited by this paper
• Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris

  1996cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death.

  1996cited by this paper
• Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

  1995cited by this paper
• Plasminogen activator expression in human atherosclerotic lesions.

  1995cited by this paper
• Hemostatic function and coronary artery disease.

  1995cited by this paper
• Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study.

  1995cited by this paper
• Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

  1995cited by this paper
• Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris.

  1995cited by this paper
• Coronary plaque disruption.

  1995cited by this paper
• Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.

  1995cited by this paper
• Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.

  1995cited by this paper
• Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease.

  1995cited by this paper
• Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture.

  1994cited by this paper
• Chronic ulcerated plaques: new insights into the pathogenesis of acute coronary disease.

  1994cited by this paper
• Do low and moderate doses of acetylsalicylic acid affect tissue plasminogen activator at rest and after exercise?

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Inflammation and Coronary Artery Disease

  1994cited by this paper
• Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells.

  1994cited by this paper
• Chronic ulcerated plaques: new insights into the pathogenesis of acute coronary disease.

  1994cited by this paper
• Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.

  1994cited by this paper
• Inflammation and coronary artery disease.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994cited by this paper
• Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells.

  1993cited by this paper
• Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries.

  1993cited by this paper
• Predictive Value of Tissue Plasminogen Activator Mass Concentration on Long‐term Mortalit in Patients With Coronary Artery Disease A 7‐Year Follow‐up

  1993cited by this paper
• Modification of atherosclerosis by agents that do not lower cholesterol.

  1993cited by this paper
• ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography.

  1993cited by this paper
• Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor.

  1993cited by this paper
• Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

  1993cited by this paper
• The Relation Between Atherosclerosis and Thrombosis

  1992cited by this paper
• Persistent generation of thrombin after acute myocardial infarction.

  1992cited by this paper
• Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

  1992cited by this paper
• The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

  1992cited by this paper
• The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

  1992cited by this paper
• Plasma triglyceride and coronary heart disease.

  1991cited by this paper
• Impaired fibrinolysis and risk of thromboembolism.

  1991cited by this paper
• Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.

  1991cited by this paper
• Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

  1991cited by this paper
• The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study.

  1991cited by this paper
• Plasminogen Activator Inhibitor-1 Levels in Patients with Chronic Angina Pectoris with or without Angiographic Evidence of Coronary Sclerosis

  1990cited by this paper
• Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.

  1990cited by this paper
• Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death.

  1989cited by this paper
• Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction.

  1989cited by this paper
• Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.

  1989cited by this paper
• Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).

  1989cited by this paper
• Identification and Distribution of Fibrinogen, Fibrin, and Fibrin(ogen) Products in Atherosclerosis: Use of Monoclonal Antibodies

  1989cited by this paper
• Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.

  1989cited by this paper
• Circadian Fluctuations of Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma of Patients with Unstable Coronary Artery Disease and Acute Myocardial Infarction

  1988cited by this paper
• Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

  1988cited by this paper
• Fibrinogen and risk of cardiovascular disease. The Framingham Study.

  1987cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• Effect of Thrombin on the Production of Plasminogen Activators and PA Inhibitor-1 by Human Foreskin Microvascular Endothelial Cells

  1987cited by this paper
• Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

  1987cited by this paper
• The pathogenesis of atherosclerosis--an update.

  1986cited by this paper
• Sandwich ELISA for t-PA antigen employing a monoclonal antibody.

  1986cited by this paper
• Coronary angioscopy in patients with unstable angina pectoris.

  1986cited by this paper
• Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

  1986cited by this paper
• Angiographic morphology and the pathogenesis of unstable angina pectoris.

  1985cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper
• Angiographie morphology and the pathogenesis of unstable angina pectoris

  1985cited by this paper
• Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death.

  1984cited by this paper
• Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi.

  1983cited by this paper
• Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture.

  1982cited by this paper
• Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.

  1980cited by this paper
• HL-A AND INFECTIVE SACROILEITIS

  1974cited by this paper
• Platelets as a source of fibroblast growth-promoting activity.

  1974cited by this paper
• Plaque fissures in human coronary thrombosis

  1966cited by this paper

• Diurnal Oscillations of Fibrinolytic Parameters in Patients with Acute Myocardial Infarction and Their Relation to Platelet Reactivity: Preliminary Insights

  2022cites this paper
• Can laser therapy modify the secretion of the tissue-type plasminogen activator and its inhibitor in an endothelial cell culture under hyperglycemia?

  2021cites this paper
• Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice.

  2020cites this paper
• Clinical Relevance of Plasma Endogenous Tissue-Plasminogen Activator and Aortic Valve Sclerosis: Performance as a Diagnostic Biomarker

  2020cites this paper
• Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case–Cohort Study on Italian Women: Results from the Moli-sani Study

  2020cites this paper
• The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease.

  2016cites this paper
• Markers of preclinical atherosclerosis and their clinical relevance.

  2015cites this paper
• Correlation of Fibrinolysis Marker of Plasma Plasminogen Activator Inhibitor type-1 and Oxidative Stress Parameters in Occurrence and Progression of coronary Artery Disease

  2015cites this paper
• Aspiryna – 115 lat po odkryciu

  2013cites this paper
• Coronary and microvascular thrombolysis with guided diagnostic ultrasound and microbubbles in acute ST segment elevation myocardial infarction.

  2011cites this paper
• Inflammatory Markers of Atherosclerosis and Risk of Cardiovascular Events As atherosclerosis

  2011cites this paper
• Prospective study of the incidence and predictors of thrombus in children undergoing palliative surgery for single ventricle physiology

  2011cites this paper
• strictly antiplatelet actions Antithrombotic properties of aspirin and resistance to aspirin: beyond

  2011cites this paper
• Extravasale Proteolyse: Funktion und Interaktion der Faktoren des fibrinolytischen Systems

  2010cites this paper
• The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk

  2010cites this paper
• PROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-α MEDIATES HIGH-FAT, DIET-ENHANCED DAILY OSCILLATION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 ACTIVITY IN MICE

  2010cites this paper
• Carotid Stenosis, Endarterectomy, and the Brain : Brain microcirculation, diffusion, and cognitive function before and after carotid endarterectomy in patients with a high-grade carotid stenosis

  2009cites this paper
• Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation

  2008cites this paper
• Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty.

  2008cites this paper
• Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

  2007cites this paper
• Effect of a cholesterol-lowering diet during pregnancy on maternal and fetal Doppler velocimetry: the CARRDIP study.

  2007cites this paper
• Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study

  2007cites this paper
• Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.

  2007cites this paper
• uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view

  2007cites this paper
• The Association of Plasma PAI-1 and tPA Antigen Concentrations with Related Cardiac Risk Factors in Patients with Acute Coronary Syndrome and Their First Degree Relatives

  2006cites this paper
• Enhanced spontaneous thrombolysis: A new therapeutic challenge

  2006cites this paper
• Spontaneous Thrombolysis: A Forgotten Determinant of Life or Death

  2006cites this paper
• The dose of aspirin for the prevention of cardiovascular and cerebrovascular events

  2006cites this paper
• Effects of enhanced counterpulsation on vascular cell release of coagulation factors.

  2005cites this paper
• Association of the Fibrinolytic System and Hemorheology with Symptoms in Patients with Carotid Occlusive Disease

  2005cites this paper
• Cholesterol diet enhances daily rhythm of Pai-1 mRNA in the mouse liver.

  2004cites this paper
• Endothelial dysfunction: methods of assessment and application to hypertension.

  2004cites this paper
• Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension.

  2003influential citation
• Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease – a 13-year follow-up

  2003cites this paper
• New in vitro model to study high glucose-dependent endothelial dysfunctions.

  2003cites this paper
• Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits.

  2003cites this paper
• Endothelial dysfunction in the pathogenesis of atherosclerosis.

  2002cites this paper
• Plasma Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Acute Myocardial Infarction

  2002cites this paper
• Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction.

  2002cites this paper
• Seasonal variation of some metabolic and haemostatic risk factors in subjects with and without coronary artery disease

  2001cites this paper
• State-of-the-Art Review: Endothelial Dysfunction in the Pathogenesis of Atherosclerosis

  2001cites this paper
• Tissue-type Plasminogen Activator (tPA)

  2001cites this paper
• Endothelial dysfunction in the pathogenesis of atherosclerosis.

  2001cites this paper
• Coronary artery disease: pathogenesis and acute coronary syndromes.

  2001cites this paper
• The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients

  2000cites this paper
• Testing for endothelial dysfunction

  2000cites this paper
• Plasmin Activation System in Restenosis: Role in Pathogenesis and Clinical Prediction?

  1999cites this paper
• Gender Differences in the Relation between Fibrinogen, Tissue-type Plasminogen Activator Antigen and Markers of Insulin Resistance: Effects of Smoking

  1999cites this paper
• Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking. D.E.S.I.R. Study Group. Data from an Epidemiological Study on Insulin Resistance Syndrome.

  1999cites this paper
• Detection of presymptomatic atherosclerosis: a current perspective.

  1999cites this paper
• State of the Art Lectures

  1998cites this paper